[34]
Novopharm argues that s. 6(8) of the
Regulations
requires that any portion of a submission ordered to be produced pursuant to s. 6(7) shall be treated confidentially. All of the portions of Novopharm's submission that will be disclosed in this proceeding were ordered to be produced pursuant to s. 6(7).